Tratamiento coadyuvante en el intervencionismo coronario percutáneo del infarto agudo de miocardio

The antiplatelet drugs, aspirin and clopidogrel, must be given as early as possible before coronary intervention. Abciximab is the most studied glycoprotein IIb/IIIa inhibitor. Its use is associated with the occurrence of fewer adverse events and better coronary artery patency before intervention. The use of thrombolytic drugs in combination with angioplasty is a promising way of extending mechanical reperfusion within the infarct but more studies must be carried out before it can be recommended. Other drugs, such as low-molecular-weight heparins and bivalirudin, have been studied in non-ST-elevation acute coronary syndrome but not in interventions for acute myocardial infarction.